At Pfizer, courage is central to the way that we work. In fact, it’s one of our values. Far from an abstract concept or goal that we aspire to, courage is a mantra that we hold ourselves to every day across our business, wherever we are in the world, and whatever our role.
In the pharmaceutical industry, resilience isn’t just important: it’s critical.
On average it takes ten years to bring a new drug to market. Often, that timeframe is significantly longer. And along the way we face setbacks, uncertainties, challenges, and many times, failures.
NEW YORK, October 17, 2022—Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 4:30 p.m. EDT on Thursday, October 20, 2022. Pfizer Vaccine leadership will review data regarding its RSV vaccine candidate presented at ID Week 2022 and to the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).
More of us than ever need science to restore not just the health of our loved ones, but life as we remember it. The power of science is the key to unlocking the answers to the world’s most challenging medical questions. Embodied by our “Science Will Win” campaign, Pfizer is at the forefront of the vital research being conducted to find treatments, cures and preventive medicines to the diseases that currently confound us.
Every year, more than 2.1 million people around the world are diagnosed with breast cancer.[1]
At Pfizer, we are so excited to welcome our first class of Breakthrough Fellows to our organization. We believe these students have so much to offer as they grow into the next generation of Pfizer leadership. To showcase the amazing talent in this program, we spoke to the Fellows themselves to learn more about their first few weeks as Pfizer. Get to know some of our Breakthrough Fellows below!
NEW YORK and MAINZ, GERMANY, September 28, 2022 —Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age.
We’re not the first business to discover how technology increases diversity, but we’ve been among the first to adopt it and make it work.
Innovation isn’t easy. Otherwise everyone could do it.
It takes many talented people putting their heads together to find inventive ways around some of the world’s biggest and toughest challenges. But, on top of being talented, everyone needs to be talented in different ways.